BR112013024957A2 - derviado de furanona ou um sal farmaceuticamente aceitável do mesmo - Google Patents

derviado de furanona ou um sal farmaceuticamente aceitável do mesmo

Info

Publication number
BR112013024957A2
BR112013024957A2 BR112013024957A BR112013024957A BR112013024957A2 BR 112013024957 A2 BR112013024957 A2 BR 112013024957A2 BR 112013024957 A BR112013024957 A BR 112013024957A BR 112013024957 A BR112013024957 A BR 112013024957A BR 112013024957 A2 BR112013024957 A2 BR 112013024957A2
Authority
BR
Brazil
Prior art keywords
optionally substituted
heterocyclic ring
hydrogen atom
furanone
pharmaceutically acceptable
Prior art date
Application number
BR112013024957A
Other languages
English (en)
Inventor
Ayako Sawa
Chika Tanaka
Masaaki Sawa
Takayuki Irie
Tokiko ASAMI
Yoko Funakoshi
Original Assignee
Carna Biosciences Inc
Sbi Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carna Biosciences Inc, Sbi Biotech Co Ltd filed Critical Carna Biosciences Inc
Publication of BR112013024957A2 publication Critical patent/BR112013024957A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

derivado de furanona ou um sal farmaceuticamente aceitável do mesmo [problema] fornecer um novo derivado de furanona e um produto farmacêutico composto do derivado de furanona. [solução] um composto representado pela fórmula (i). (na fórmula, a representa-coor1 ou um átomo de hidrogênio; r1 representa um átomo de hidrogênio, um grupo de hidrocarboneto opcionalmente substituído, ou um anel heterocíclico opcionalmente substituído; r2 e r3 podem ser os mesmos ou diferentes e cada um representa um átomo de hidrogênio, um grupo de hidrocarboneto opcionalmente substituído, um grupo fenila opcionalmente substituído, um anel heterocíclico opcionalmente substituído, um anel heterocíclico fundido opcionalmente substituído, ou um grupo amino opcionalmente substituído; ou alternativamente, r2 e r3, podem formar um anel heterocíclico opcionalmente substituído ou um anel heterocíclico fundido opcionalmente substituído juntos com um átomo de hidrogênio ou um átomo de halogênio; em relação a isto quando a representa-coor1, r2 e r3 não são grupos amino opcionalmente substituídos ao mesmo tempo e quando a representa um átomo de hidrogênio, r3 representa um átomo de hidrogênio.
BR112013024957A 2011-03-31 2012-03-30 derviado de furanona ou um sal farmaceuticamente aceitável do mesmo BR112013024957A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011080185 2011-03-31
PCT/JP2012/058636 WO2012133802A1 (ja) 2011-03-31 2012-03-30 新規フラノン誘導体

Publications (1)

Publication Number Publication Date
BR112013024957A2 true BR112013024957A2 (pt) 2016-12-20

Family

ID=46931496

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013024957A BR112013024957A2 (pt) 2011-03-31 2012-03-30 derviado de furanona ou um sal farmaceuticamente aceitável do mesmo

Country Status (12)

Country Link
US (3) USRE48140E1 (pt)
EP (1) EP2692728B1 (pt)
JP (3) JP5659356B2 (pt)
KR (1) KR101964479B1 (pt)
CN (1) CN103459388B (pt)
AU (3) AU2012233246B2 (pt)
BR (1) BR112013024957A2 (pt)
CA (1) CA2830148C (pt)
DK (1) DK2692728T3 (pt)
ES (1) ES2687450T3 (pt)
MX (1) MX344474B (pt)
WO (1) WO2012133802A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX344474B (es) 2011-03-31 2016-12-16 Carna Biosciences Inc Nuevos derivados de furanona.
EP3100742B1 (en) * 2014-01-31 2020-05-20 Carna Biosciences Inc. Anticancer agent composition comprising a cdc7 inhibitor and a wee1 inhibitor
CN104744353B (zh) * 2015-03-31 2017-11-24 山东友帮生化科技有限公司 2‑氨基‑3‑碘‑5‑氯吡啶的合成方法
AU2017354372A1 (en) * 2016-11-04 2019-06-20 Carna Biosciences, Inc. Furanone derivates and methods of use thereof
GB201807147D0 (en) 2018-05-01 2018-06-13 Oncologica Uk Ltd Therapeutic combination
CA3113621A1 (en) * 2018-09-24 2020-04-02 Sierra Oncology, Inc. Methods of treatment of cancer comprising cdc7 inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6987113B2 (en) 1997-06-11 2006-01-17 Sugen, Inc. Tyrosine kinase inhibitors
US6335342B1 (en) * 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
ES2304531T3 (es) 2002-07-17 2008-10-16 Pfizer Italia S.R.L. Derivados heterobiciclicos de pirazol como inhibidores de quinasa.
US20050101623A1 (en) 2003-07-23 2005-05-12 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
CA2534496A1 (en) 2003-08-08 2005-02-17 Ermes Vanotti Pyrimidylpyrrole derivatives active as kinase inhibitors
US20050043346A1 (en) 2003-08-08 2005-02-24 Pharmacia Italia S.P.A. Pyridylpyrrole derivatives active as kinase inhibitors
FR2876103B1 (fr) 2004-10-01 2008-02-22 Aventis Pharma Sa Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
BRPI0518158A (pt) * 2004-10-14 2008-11-04 Hoffmann La Roche tiazolinonas de azaindol como agentes anti-cáncer
US20060122232A1 (en) * 2004-12-06 2006-06-08 Development Center For Biotechnology 4-Hydroxyfuroic acid derivatives
US7371862B2 (en) * 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
CN101410387B (zh) 2006-03-27 2013-12-18 内尔维阿诺医学科学有限公司 作为激酶抑制剂的吡啶基-和嘧啶基-取代的吡咯-、噻吩-和呋喃-衍生物
FR2907120B1 (fr) 2006-10-12 2013-01-11 Sanofi Aventis Nouveaux derives imidazolones,leur preparation a titre de medicaments,compositions pharmaceutiques,utilisation comme inhibiteurs de proteines kinases notamment cdc7
WO2008109443A2 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting cdk2 gene expression and uses thereof
US20090298820A1 (en) 2008-05-28 2009-12-03 Wyeth 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2010030727A1 (en) * 2008-09-10 2010-03-18 Wyeth Llc 3-substituted-1h-indole, 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
CN102471339A (zh) 2009-07-15 2012-05-23 雅培制药有限公司 激酶的吡咯并吡啶抑制剂
TW201127384A (en) 2009-11-18 2011-08-16 Nerviano Medical Sciences Srl Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent
EP2588478A1 (en) 2010-06-29 2013-05-08 SBI Biotech Co., Ltd. Azaindole derivative
MX344474B (es) * 2011-03-31 2016-12-16 Carna Biosciences Inc Nuevos derivados de furanona.
EP3100742B1 (en) 2014-01-31 2020-05-20 Carna Biosciences Inc. Anticancer agent composition comprising a cdc7 inhibitor and a wee1 inhibitor

Also Published As

Publication number Publication date
ES2687450T3 (es) 2018-10-25
KR20140056164A (ko) 2014-05-09
AU2017203986B2 (en) 2019-02-28
EP2692728A1 (en) 2014-02-05
CN103459388A (zh) 2013-12-18
JP2015042663A (ja) 2015-03-05
DK2692728T3 (en) 2018-10-08
JP5891576B2 (ja) 2016-03-23
US8742113B2 (en) 2014-06-03
JPWO2012133802A1 (ja) 2014-07-28
AU2012233246A1 (en) 2013-10-10
CN103459388B (zh) 2015-11-25
JP6256927B2 (ja) 2018-01-10
CA2830148C (en) 2020-07-28
USRE46815E1 (en) 2018-05-01
EP2692728A4 (en) 2014-08-20
KR101964479B1 (ko) 2019-04-01
JP2016084363A (ja) 2016-05-19
AU2012233246B2 (en) 2017-03-30
CA2830148A1 (en) 2012-10-04
AU2019203483A1 (en) 2019-06-06
EP2692728B1 (en) 2018-07-04
AU2017203986A1 (en) 2017-07-06
JP5659356B2 (ja) 2015-01-28
US20140018533A1 (en) 2014-01-16
MX344474B (es) 2016-12-16
WO2012133802A1 (ja) 2012-10-04
MX2013010962A (es) 2014-04-25
USRE48140E1 (en) 2020-08-04

Similar Documents

Publication Publication Date Title
BR112019006816A8 (pt) Compostos de benzo[b]tiofeno como agonistas de sting, composição farmacêutica e uso dos mesmos
CY1122614T1 (el) 11-υδροξυλ-6-υποκατεστημενα-παραγωγα χολικων οξεων και συζευγματα αμινοξεων αυτων ως ρυθμιστες υποδοχεων χ φαρνεσοειδων
CY1119220T1 (el) Μονοκυκλικο παραγωγο πυριδινης
CO6341631A2 (es) Derivados de 1,2,4 - oxadiazol y su uso terapéutico
BR112013024957A2 (pt) derviado de furanona ou um sal farmaceuticamente aceitável do mesmo
BR112014013974A8 (pt) derivados de sulfonamida benzílicos como moduladores de rorc
IN2014MN01897A (pt)
MX2011011875A (es) Compuesto de carboxamida heterociclica diamino.
BR112014006660A2 (pt) novos derivados de dihidroquinolina-2-ona bicíclicos
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
BR112014010644A2 (pt) novos derivados de aril-quinolina
TW200738607A (en) Sulfonamide derivatives, preparation thereof and therapeutic use thereof
BR112017022654A2 (pt) derivado heterocíclico de 6 membros e composição farmacêutica compreendendo o mesmo
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
BR112013010552A2 (pt) derivado de piridina e agente medicinal
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
BR112015016580A2 (pt) composto heterocíclico contendo nitrogênio ou sal deste
BR112016001979A2 (pt) composto de tetrazolinona e uso do mesmo
EA201170093A1 (ru) Замещенные n-оксидпиразиновые производные
BR112013018732A2 (pt) novos derivados de amida de aril-benzocicloalquila
CY1124643T1 (el) Νεα ενωση και φαρμακευτικα αποδεκτο αλας αυτης
EA201892264A1 (ru) Производные тетрагидроизохинолина
NO20080033L (no) Kinolinderivater som NK3-antagonister
PH12014502663B1 (en) Aromatic heterocyclic derivative and pharmaceutical
MX2013003749A (es) Derivados de 1,4-oxazepano.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B25H Request for change of headquarter rejected

Owner name: SBI BIOTECH CO., LTD (JP) , CARNA BIOSCIENCES, INC